EMA Withdrawn: Indimacis 125 (igovomab) — CIS bio international

View source ↗

Summary

EMA status indicates Indimacis 125 (igovomab) has been withdrawn from the market.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Neoplasms

Drugs mentioned

• Indimacis 125 (igovomab)

Snippet

Status: Withdrawn. Therapeutic area: Radionuclide Imaging;Ovarian Neoplasms. MAH: CIS bio international. Decision date: 31/12/2009